Drug Type Small molecule drug |
Synonyms MU 1630, MU1630 |
Target |
Action inhibitors |
Mechanism CK1 inhibitors(Casein kinase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis | Preclinical | Czechia | 01 Nov 2025 | |
| Huntington Disease | Preclinical | Czechia | 01 Nov 2025 | |
| Parkinson Disease | Preclinical | Czechia | 01 Nov 2025 | |
| Prostatic Cancer | Preclinical | Czechia | 01 Nov 2025 | |
| Colorectal Cancer | Preclinical | Czechia | 23 Apr 2024 | |
| Melanoma | Preclinical | Czechia | 23 Apr 2024 | |
| Pancreatic Cancer | Preclinical | Czechia | 23 Apr 2024 | |
| Triple Negative Breast Cancer | Preclinical | Czechia | 23 Apr 2024 | |
| Acute Myeloid Leukemia | Preclinical | Czechia | 20 Oct 2023 |





